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Identification of a First Human
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Restricted to HLA-A∗0201 Allele
Maria Malm, Timo Vesikari and Vesna Blazevic*
Faculty of Medicine and Life Sciences, Vaccine Research Center, University of Tampere, Tampere, Finland
Norovirus (NoV) causes a substantial global burden of acute gastroenteritis in all
age groups and the development of NoV vaccine is a high priority. There are still
gaps in understanding of protective NoV-specific immunity. Antibody mediated immune
responses have been widely studied, but in contrast, the research on NoV-specific
human T cell-mediated immunity is very limited. We have recently reported NoV capsid
VP1-specific 18-mer peptide (134SPSQVTMFPHIIVDVRQL151) to induce strong CD8+
T cell immune responses in healthy adult donors. This work extends to identify the
precise NoV T cell epitope and the restricting human leucocyte antigen (HLA). Pentamer
technology was used to detect HLA-A∗0201-restricted T cell-mediated responses to
10-mer peptide 139TMFPHIIVDV148 of four healthy adult blood donors. Immunogenicity
of the 10-mer epitope was confirmed by ELISPOT IFN-γ and intracellular cytokine
staining (ICS) on flow cytometry. A population of CD3+CD8+ T lymphocytes binding
to HLA-A∗0201/TMFPHIIVDV pentamers was identified in two HLA-A∗0201-positive
donors. Recognition of the 10-mer epitope by T cells resulted in a strong IFN-γ secretion
as shown by ELISPOT assay. In addition, ICS confirmed that high proportion (31 and
59%) of the TMFPHIIVDV epitope-responsive CD3+CD8+ T cells in the two donors had
multifunctional phenotype, simultaneously producing IFN-γ, IL-2 and TNF-α cytokines.
In the present study novel human NoV HLA-A∗0201-restricted minimal 10-mer epitope
139TMFPHIIVDV148 in the capsid VP1 was identified. The HLA-peptide pentamer staining
of T cells from healthy donor PBMCs and cytokine responses in ex-vivo ELISPOT and
ICS assays suggest that this epitope is recognized during NoV infection and activates
memory phenotype of the epitope-specific multifunctional CD8+ T cells. The importance
of this epitope in protection from NoV infection remains to be determined.
Keywords: norovirus, CD8T cell epitope, HLA-A2∗0201, multifunctional T cells, pentamer, ELISPOT IFN-gamma,
cellular immunity
INTRODUCTION
Noroviruses (NoV) are group of very contagious viruses that cause >90% of non-bacterial
and approximately half of all-cause epidemic gastroenteritis worldwide. NoV gastroenteritis is a
significant public health problem with high clinical and economic costs, that is estimated to cause
over 200,000 deaths annually, mainly in resource-limited countries (1). Despite scientific efforts
and increasing awareness of NoV burden, there is no vaccine available yet (2, 3). NoV exhibits a
great genetic diversity with six currently recognized genogroups (GI-GVI), humanNoVs belonging
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mainly to GI and GII, that include over 30 genotypes and
numerous intra-genotype variants (4). GII.4 genotype has been
predominant since the mid-90s, including pandemic variants
US 1995/96, Farmington Hills 2002, Hunter 2004, New Orleans
(NO) 2009, and most recently, Sydney 2012 (5). GII.4 variants
share >95% of their VP1 capsid amino acid (aa) sequence,
whereas <85% of the capsid aa are identical between different
genotypes (6). The antigenic diversity of NoVs is likely to
have major impact on evading host immune responses and
complicates designing of NoV vaccines. NoV research is further
limited due to the lack of small animal model and efficient NoV
propagation in cell culture (7, 8), but spontaneously formed
NoV VP1 virus-like particles (VLPs) are successfully utilized as
viral surrogates for assaying immune responses and as vaccine
candidates (9, 10).
NoV infections cause acute but self-limited illness already
at early age and several consecutive infections occur frequently
(11–13). Protective immunity and clearance of NoV infections
are not well-characterized (1, 2). Even though there is some
indication of pre-existing antibodies conferring protection (14)
the level of serum NoV-specific antibodies is not directly
linked to protection from infection (15). The best correlate of
protection from NoV infection identified so far are blocking
(neutralizing) antibodies, that are able to block the binding of
NoV VLPs to the putative receptors, histo-blood group antigens
(HBGA’s) (15). NoV-specific antibodies are cross-reactive to
some extent within genogroups however, blocking antibodies
are mostly genotype-specific with low protective capacity against
more distinct strains (1). Although NoV-specific antibodies are
extensively studied very little is published on human T cell
immunity to NoV and its’ role in protection (16–19). Studies
using a murine norovirus (MNV)-mouse model have suggested
T cell-mediated immunity to be important in clearance of
MNV infection (20, 21). To this end, cytotoxic CD8+ T cell-
mediated immune responses may provide substantial protection
against serologically distinct viruses via recognition of cross-
reactive, conserved epitopes, such as observed in influenza virus
infection (22).
Using matrix peptide approach we have recently identified a
NoV-specific 18-mer peptide (134SPSQVTMFPHIIVDVRQL151)
containing CD8+ T cell epitope likely restricted to human
leukocyte antigen (HLA)-A∗0201 allele (17). Furthermore,
peptide binding prediction tools have predicted 10 amino acid
(aa) stretch as a minimal epitope (139TMFPHIIVDV148). In here,
experiments were undertaken to experimentally confirm the
recognition of the 10-mer epitope and its presentation by the
HLA-A∗0201 allele.
MATERIALS AND METHODS
Blood Donors and Cell Isolation
Four healthy adults (age 35–45, laboratory personnel)
volunteering in a study recently conducted by our laboratory
were selected based on their CD8+ T cell responses to NoV GII.4
VP1-specific 18-mer peptide 134SPSQVTMFPHIIVDVRQL151
(originally named 99-20) recently described (17). The two
peptide responders were HLA typed as HLA-A∗02:01
carriers (17). The cells of the two donors identified as non-
responders to the 18-mer peptide were used as negative
controls. Peripheral blood mononuclear cells (PBMCs) of the
heparin blood sample were obtained by Ficoll-Pague PLUS
(GE Healthcare, Little Chalfont, United Kingdom) density
gradient centrifugation. PBMCs were frozen in 10% DMSO
in fetal bovine serum (FBS) using freezing container (Mr.
FrostyTM, Thermo Scientific,Waltham, MA, United States) with
controlled rate of cooling at −80◦C and transferred to liquid
nitrogen. Prior to analysis, PBMCs were thawed, washed, and
resuspended in culture medium (CM) containing RPMI 1640
with Glutamax R© and HEPES (GibcoTM by Thermo Fisher
Scientific) supplemented with 10µg/ml Gentamicin (GibcoTM)
and 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis,
MO, United States). The samples tested here are collected at
a single bleed. Each sample aliquot was tested simultaneously
by pentamer staining, enzyme-linked immunosorbent spot
interferon-gamma (ELISPOT IFN-γ) assay and intracellular
cytokine staining (ICS) assays, at least two times. Written
informed consent was obtained from each volunteer prior to the
sample collection in accordance with the Declaration of Helsinki.
No approval by an ethics committee was required as per the local
legislation.
Synthetic Peptides and Pentamers
To predict the optimal HLA-A∗02:01 allele binding
epitope within the 18-mer NoV-specific peptide
134SPSQVTMFPHIIVDVRQL151, artificial neural networks
(ANN) (23) implemented at Immune Epitope Database and
Analysis Resource (IEDB) was employed (24–26). A 10-mer high
binding affinity sequence 139TMFPHIIVDV148 was identified
(17) and the peptide was synthetized with purity >75%
(Synpeptide Co. Ltd, Shanghai, China). SYFPEITHI prediction
algorithm (http://www.syfpeithi.de) (27) was used for scoring
the peptide affinity for HLA-A∗0201 allele, as a binding score
of >21 ensures synthesis of a custom pentamer by Proimmune
Ltd. (Oxford, United Kingdom). HLA-A∗0201/TMFPHIIVDV
pentamer (Pro5 R© MHC Class I Pentamer) labeled with R-
phycoerythrin (R-PE) was synthetized by Proimmune Ltd. In
addition, HLA-A∗0201 negative control pentamer conjugated
to R-PE was synthetized as well. The degree of conservation
of the 10-mer epitope among different NoV genotypes and
genogroups was investigated using Basic Local Alignment Search
Tool (BLAST) for sequence identity. Evolutionary analyses
of the major capsid VP1 aa sequence of the aligned NoV
genotypes were conducted in MEGA X (28). The evolutionary
distances were computed using the Poisson correction
method (29).
Pentamer Staining
PBMCs were treated for 10min with Human BD Fc Block
to prevent non-specific staining. To discriminate viable from
non-viable cells, Horizon Fixable Viability stain 780 was
used according to manufacturer’s instructions. The cells (1
× 106) were incubated for 30min on ice with either HLA-
A∗0201/TMFPHIIVDV pentamer or negative control pentamer,
using 0.25 or 0.5 µg of the pentamers per condition. Cells were
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further stained with monoclonal antibodies against human CD3
(clone UCHT1, fluorescein isothiocyanate (FITC) conjugate)
and CD8a (clone RPA-T8, PerCP Cy5.5 conjugate) for 30min
on ice. All reagents used for staining were purchased from
BD Pharmingen (San Jose, CA, United States). After washing
the cells were resuspended in 1% FBS, 2.5% formaldehyde in
PBS for flow cytometry acquisition. At least 400 000 events
were acquired for analysis on a 2-laser FACS CantoII flow
cytometer (BD) with FACSDiva Software V 6.1.3 (Becton
Dickinson, Heidelberg, Germany). Data were analyzed by FlowJo
software version 10.1 (Tree Star, San Carlos, CA, United States).
Lymphocytes were gated according to forward/sideward scatter
(FSC/SSC) and dead cells were excluded by gating on
the population negative for the viability dye. CD3+CD8+
population was further plotted on SSC-A vs. pentamer
population.
ELISPOT IFN-γ Assay
PBMCs of the four donors were assayed in an ELISPOT
assay for IFN-γ production as previously described (17). The
cells were stimulated with increasing concentrations of 10-mer
139TMFPHIIVDV148 peptide (0.05, 0.1, 0.5, 1, 2, and 4µg/ml
final concentration), 4µg/ml of 18-mer peptide 99-20, 4µg/ml
irrelevant 9-mer peptide (negative control) or 50µg/ml of
phytohemagglutinin (PHA, positive control). Briefly, ninety-six-
well nitrocellulose filter plates (Millipore) were coated with anti-
human IFN-γ capture antibody (Mabtech) and blocked with
10% FBS in CM. PBMCs (0.2 × 106 cells/well) were plated
with stimulants and incubated for 20 h at +37◦C and 5% CO2.
Biotinylated anti-human IFN-γ antibody (Mabtech) followed
by streptavidin-HRP (BD, New Jersey, United States) was used
for detection. The spots were developed with Vector Nova
Red substrate (Vector Labs, Burlingame, United States) and
the plates were analyzed using ImmunoSpot Series II analyzer
(CTL Europe, Leinfelden-Echterdingen, Germany). The results
are expressed as mean spot forming cells (SFC)/106 PBMCs of
the duplicate wells.
Intracellular Cytokine Staining (ICS)
An ICS assay was employed to quantify IFN-γ, TNF-α, and
IL-2 producing CD3+ CD8+ T cells. PBMCs were stimulated
according to the previously published protocol (17) with 4µg/ml
of 10-mer peptide 139TMFPHIIVDV148, 4µg/ml irrelevant
9-mer peptide (negative control) or 1µg/ml Staphylococcal
enterotoxin B (SEB, Sigma) in the presence of 1µg/ml CD28 and
1µg/ml CD49d costimulatory antibodies (BD Biosciences, San
Jose, CA, United States). PBMCs incubated in CM supplemented
with the costimulatory antibodies only were used as additional
control. The protein transport inhibitor brefeldin A (GolgiPlug,
BD Biosciences, San Jose, CA, United States) at a concentration
of 10µg/ml was added after 2 h and the incubation was continued
for 16 h at 37◦C. After stimulation, the cells were treated
with EDTA for 15min and washed with FACS Stain buffer.
Prior to fixation and permeabilization for ICS, PBMCs were
blocked for non-specific staining, stained for viable/non-viable
discrimination and surface markers CD3 and CD8a as described
above for the pentamer staining. BD Fixation/Permeabilization
solution was used according to the manufacturer’s instructions
and cells were intracellularly stained with the mixture of IFN-γ
(clone 4S.B3) PE-Cy7 conjugate, IL-2 (clone MQ1-17H12) PE-
conjugate, and TNF-α (clone MAb11) allophycocyanin (APC)-
conjugate in 50 µl Perm/Wash buffer for 30min on ice in
the dark. Cells were resuspended in FACS Staining Buffer for
acquisition and analysis using FACS CantoII flow cytometer
and FACSDiva Software V 6.1.3. All reagents used for ICS were
purchased from BD Pharmingen (San Jose, CA, United States).
The data analysis was performed using FlowJo software version
10.1.
RESULTS
The 10-mer Minimal Epitope Prediction
and Conservation
At the outset of our study, an 18-mer NoV VP1-specific CD8+ T
cell epitope (99-20, 134SPSQVTMFPHIIVDVRQL151) had been
identified in two subjects, both having HLA-A∗0201 allele. When
analyzed by IEDB database ANN method, a 10 aa sequence
139TMFPHIIVDV148 within the 18-mer showed the highest
binding affinity of IC50 21.5 nM (Table 1), whereas all other
predicted sequence lengths indicated affinity >80 nM (data not
shown). Peptides with IC50 < 50 nM are considered high affinity
and <500 nM intermediate affinity (30). Congruently, the same
10-mer epitope was identified to have the highest binding affinity
by SMM method [data not shown (23)]. SYFPEITHI prediction
algorithm confirmed a score of 27 for the peptide affinity for
HLA-A∗0201 allele (Table 1). When comparing the aa sequence
of different NoV genotypes (Table 1) the 10-mer epitope was
found to be highly conserved among different GII.4 variants
and also more distant NoV genotypes belonging to GII and
GI. The phylogenetic distances of the NoV genotypes compared
in the Table 1 are shown in Figure 1. In addition, the 10-mer
epitope sequence in all genotypes belonging to GI and GII NoV
listed in the Table 1 also had good affinity binding scores for
HLA-A∗0201 allele regardless of up to three aa substitutions
compared to the GII.4-1999 10-mer sequence. On the contrary,
the 10-mer sequence in the human GIV 2010 NoV had a
unique substitution 140M to 140Q which seemed to abolish its
binding affinity resulting in IC50 552.6 nM and syfpeithi score
17 (Table 1). In addition, a change of the aa 148V to 148D at
the c-terminus of the empirical 10-mer peptide abolished the
predicted binding completely. This is not surprising as the aa
at positions 140 and 148 are reported anchoring positions for
HLA-A∗0201 binding (31–33). In addition, deletions at the each
terminus of the peptide affected the predicted binding capability
of the peptide.
CD8+ T Lymphocytes Bind the 10-mer
Peptide 139TMFPHIIVDV148 in the Context
of HLA-A∗0201
The frequency of T cells specific for 139TMFPHIIVDV148
10-mer in the context of HLA-A∗0201 allele was analyzed
by direct binding to pentamer A∗0201/TMFPHIIVDV R-PE
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TABLE 1 | Conservation and HLA-A2*0201 allele binding affinity prediction of the norovirus 10-mer epitope.
Norovirus Genotype Accession number 10-mer aa sequence
(aa 139–148)
Identity % IC50 nM (ANN)
a Syfpeithi scoreb
GII.4-1999 AAD40490.1 TMFPHIIVDV 100 21.5 27
GII.4 Farmington Hills 2002 AFJ04708.1 TMFPHIIVDV 100 21.5 27
GII.4 Apeldoorn 2003 BAF74517.1 TMFPHIIVDV 100 21.5 27
GII.4 Hunter 2004 AAZ31376.2 TMFPHIIVDV 100 21.5 27
GII.4 New Orleans 2009 ADD10375.1 TMFPHIIVDV 100 21.5 27
GII.4 Sydney 2012 AFV08795.1 TMFPHIVVDV 90 28.22 27
GII.17 Kawasaki308 BAR42289.1 TMLPHLIVDV 80 30.14 28
GI.3 2002 AAL12962.1 TMFPHVIADV 80 14.44 27
GII.12 Wortley 1990 CAB89099.1 TMFPHVIIDV 80 31.84 25
GII.10 Vietnam026 2005 AAT12445.1 TMFPHVIIDV 80 31.84 25
GII.1 1971 AFS33555.1 TMFPHVIIDV 80 31.84 25
GII.2 2014 BAV19452.1 TMFPHVIIDV 80 31.84 25
GII.3 1976 AED02039.1 TMCPHVIVDV 80 278.56 26
GI.1 West Chester 2001 AAS86807.1 TLFPHVIADV 70 16.87 29
Human GIV 2010 AFJ21376.1 TQFPHVIIDV 70 552.6 17
Not existing TMFPHIIVDD 90 17260.44 17
9-mer _MFPHIIVDV 90 4645.06 16
9-mer TMFPHIIVD_ 90 9837.8 15
a Inhibitory concentration (IC)50 values were obtained using IEDB analysis resource ANN aka NetMHC (ver. 4.0) tool.
b Syfpeithi score was derived from the Epitope Prediction tool by http://www.syfpeithi.de/ Bolded letters indicate the reported anchor residues of HLA-A2*0201 allele binding epitopes
(31, 32). Underlined letters indicate the aa changes with respect to GII.4-1999-derived 10-mer epitope. Italic font denotes sequences with no affinity binding to HLA-A2*0201.
FIGURE 1 | Phylogenetic analysis of norovirus major capsid protein VP1
amino acid sequences. The tree was inferred by Neighbor-Joining method
with a bootstrap of 500 by using MegaX. The scale bar shows the genetic
distance, expressed as amino acid substitutions per site.
using four-color flow cytometry. PBMCs of the two HLA-
A∗0201 positive donors previously responding to the 18-mer
peptide 99-20 had frequency of 0.51% (Donor 1) and 1.52%
(Donor 2) (Figure 2) pentamer-binding T cells of the live
CD3+CD8+ gated lymphocytes. At the same time, the CD8+
T cells of the control donors non-responders to the 99-20, did
not bind to A∗0201/TMFPHIIVDV pentamer (Figure 2). The
negative control pentamer did not show non-specific binding
(Figure 2).
The 10-mer 139TMFPHIIVDV148 Epitope
Induces Strong IFN-γ Response in
HLA-A∗0201 Positive Donors
IFN-γ-secreting lymphocytes specific for 139TMFPHIIVDV148
10-mer peptide were enumerated by ex-vivo ELISPOT assay
with increasing concentration of the 10-mer peptide. Robust
IFN-γ response to the 10-mer peptide was observed for the
two HLA-A∗0201 positive donors (Figure 3) but not for the
two control donors (data not shown). A dose response was
observed up to 1.0µg/ml concentration of the peptide and
also very low concentration (0.05µg/ml) stimulated high IFN-
γ secretion (donor 1, 260 SFC/106 cells; donor 2, 293 SFC/106
cells). IFN-γ production was not observed in the cells stimulated
with the irrelevant 9-mer peptide or CM only (SFC/106 cells
<50) (Figure 3A–C). All donors responded strongly to the
positive control PHA (IFN-γ SFC/106 cells >2000, data not
shown).
The 10-mer 139TMFPHIIVDV148 Epitope
Induces Multifunctional CD8+ T Cells
Producing IFN-γ, IL-2, and TNF-α
Along with quantification of the epitope-specific CD8+ T cells
with HLA-A∗0201 pentamer and IFN-γ ELISPOT, immune
responses to 10-mer peptide were characterized by ICS of
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FIGURE 2 | Pentamer staining of norovirus-derived 139TMFPHIIVDV148 epitope-specific CD8+ T cells. Peripheral blood mononuclear cells (PBMCs) from two
HLA-A*0201-positive healthy adult donors and the negative control were directly stained using 0.25 and 0.5 µg HLA-A*0201/TMFPHIIVDV pentamer or negative
control pentamer. The dot plots show the percentage of pentamer-positive T cells for two HLA-A*0201-positive donors and a representative negative control donor
after gating on live CD3+CD8+ T lymphocyte population.
IFN-γ, IL-2, and TNF-α (Figure 4). The gating strategy for
ICS analysis is shown in Figure 4. The viability of the
lymphocytes was >98% and approximately 30% of the viable
CD3+ lymphocyte population were CD8+ T cells. CD8+ T cells
were further segregated into IFN-γ+ and IFN-γ− population
and plotted for the expression of IL-2 and TNF-α. Robust
cytokine response by CD3+CD8+ T cells toward 10-mer
epitope in donor 1 (Figure 4A) and donor 2 (Figure 4B) but
not in two control donors (data not shown) was observed.
Both donors had CD8+ T cells producing single, double,
and triple cytokines (Figures 4A,B). App. 1% of the CD8+
T cells of both donors produced IFN-γ in response to the
10-mer epitope (Figure 4) whereas irrelevant control peptide
induced no IFN-γ (<0.05%, data not shown). The 10-mer
epitope induced multifunctional CD8+ T cells in both donors,
donor 1 had ∼30% triple cytokine (IFN-γ+, TNF-α+, and IL-
2+) secreting CD3+CD8+ T cells, while donor 2 had ∼60%
of the triple-positive CD8+ T cells. Strong IFN-γ, IL-2, and
TNF-α response was observed in both CD8+ and CD8−
PBMCs against positive control SEB in all tested donors (not
shown).
DISCUSSION
Despite significant efforts to define correlates of protection to
NoV infection (1, 2), the role of T lymphocytes in protection
and clearance of NoV infection is still largely unexplored area,
with only few papers published so far (16–19, 34). We have
recently tested ten healthy volunteer donors for NoV GII.4
capsid VP1-specific T cell responses using matrix peptide pools
and found two CD8+ T cell responders to 18-mer NoV-
specific peptide (134SPSQVTMFPHIIVDVRQL151, 99-20) (17).
In here, we defined a 10-mer 139TMFPHIIVDV148 minimal
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FIGURE 3 | Norovirus epitope 139TMFPHIIVDV148 –specific enzyme-linked immunosorbent spot (ELISPOT) interferon-gamma (IFN-γ) responses. PBMCs of Donor 1
(A,B) and Donor 2 (A,C) positive for HLA-A*0201 allele were stimulated with an increasing concentration (0–4µg/ml) of the 10-mer epitope peptide, 4µg/ml irrelevant
9-mer peptide (Ctrl), or left unstimulated (CM, culture media). Images of the ELISPOT replicate wells with the stained spot-forming cells (SFC) are shown (A). Mean
SFC/106 PBMCs of two replicate wells with the standard errors of the mean for Donor 1 (B) and Donor 2 (C). The cut-off line (dotted line) indicates the positive
SFC/106 value of ≥50 SFC/106 cells and twice above the background control (CM only wells).
epitope within this sequence and its restriction to HLA-A∗0201
allele.
While the 10-mer 139TMFPHIIVDV148 epitope is derived
from GII.4-1999 strain (17), the alignment with several
other GII.4 variants showed epitope sequence to remain
invariable until 2012 (Table 1). Interestingly, alignment with
other quite distant genotypes (Figure 1) even belonging to GI
viruses, indicated high degree of conservation of the epitope.
Importantly, up to three aa substitutions as in the GI.1 West
Chester 2001 NoV do not necessarily reduce the binding
affinity to HLA-A∗0201, depending on the aa position and
characteristics. Aa at the position 6 and 8 of the 10-mer
showed most variability among the aligned genotypes, however,
these changes did not lead to considerable change in binding
affinity predictions. However, a change at aa position 2 from a
hydrophobic (M) to a polar aa (Q) in a human GIV 2010 NoV
and at aa position 9 fromV to D in an empirical sequence seemed
to drastically abolish binding affinity. This is not surprising as
HLA-A∗0201 binding epitopes have a restricted size of 9/10 aa
and hydrophobic anchor residues at positions 2 and 9/10 likewise
the epitope identified in this study. The NoV 10-mer epitope
contains methionine (M) at position 2 and valine (V) at position
10 which is described as a typical C-terminal anchor residue
(31–33).
Direct staining of PBMCs with HLA-A∗0201 pentamer
loaded with 139TMFPHIIVDV148 peptide attested relatively high
frequency of circulating NoV capsid-specific memory CD8+
T cells in two HLA-A∗0201 positive healthy donors (0.51 and
1.52% of CD3+CD8+ gated lymphocytes, respectively). HLA-A2
is the most prevalent MHC allele family in human population
and the gene frequency of HLA-A∗02:01 is especially high in
Caucasians (>20%), and other western ethnic groups (African
Americans 12%, Hispanics 23%, North American natives 21%)
(35–37), further emphasizing the importance of the identified
epitope. However, it has been reported that only a small portion
of the peptides with predicted and experimentally confirmed
high affinity binding, are actually capable to induce T-cell
responses (38). Therefore, the utilization of functional assays is
essential for determining the immunogenicity of an epitope. To
that end, the functionality of T cell immune responses to 10-mer
epitope were determined by two functional assays, ELISPOT
IFN-γ and ICS. The results of ELISPOT IFN-γ assay showed
robust NoV VP1 10-mer epitope-specific CD8+ T cell immune
responses in HLA-A∗0201-positive individuals, whereas control
donors were negative. Titration of 10-mer peptide down to
0.05µg/ml revealed high avidity of CD8+ T cells to 10-mer
peptide. These results were expanded using ICS assay to detect
CD8+ T cells secreting cytokines IFN-γ, IL-2, and TNF–α. By
this approach, the presence of circulating monofunctional and
polyfunctional memory CD8+ T lymphocytes specific for 10-
mer NoV epitope was detected in HLA-A∗0201-positive healthy
donors. Polyfunctional CD8+ T cells that produce more than
one immune mediator, are associated with protection from viral
infections, such as HIV-1 and human herpes virus (39–41). In
the future we aim to utilize the pentamer technology to validate
CD8+ T cell responses in a larger number of serologically
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FIGURE 4 | Functional characterization of norovirus 10-mer epitope 139TMFPHIIVDV148 –specific CD8+ T cells by intracellular cytokine staining (ICS). Production of
IL-2, IFN-γ, and TNF-α measured by ICS after 16 h stimulation of the PBMC with the peptide 139TMFPHIIVDV148 (4µg/ml). Shown are the results of the two
HLA-A*0201-positive donors, Donor 1 (A) and Donor 2 (B). Live epitope-specific CD3+ CD8+ T cells were segregated into IFN-γ+ and IFN-γ− T cells. Seven distinct
populations, based on production of the cytokines in any combination are depicted on the pie charts and the accompanying tables. Fractions of the cells producing
one, two, or three cytokines are derived from the plotted IFN-γ+ and IFN-γ− populations.
positive NoV-infected HLA-A∗02:01 positive subjects to
strengthen the clinical significance of the finding in this
study.
Pentamer staining, ELISPOT IFN-γ and ICS assays,
performed simultaneously using the same sample of each
donor, resulted in highly congruent data supporting high
immunogenicity of the novel NoV 139TMFPHIIVDV148 CD8+
T cell epitope. Many viral infections are not contained by
antibody responses alone and it is likely that T cell responses
play a role in clearance of NoV infection and may have a role in
protective immunity as well. Virus-specific CTL responses play a
crucial role in a clearance of many other viral infections such as
human immunodeficiency virus-1 (HIV-1) (40, 42, 43), influenza
(22, 44) and human papilloma virus (45). Patients with chronic
hepatitis B (HBV) infection typically lack effective HBV-specific
T cells, whereas fully recovered patients display strong CD8+
T-cell responses (46).
To conclude, the present work describes the first human
NoV CD8+ T cell epitope 139TMFPHIIVDV148 restricted to
HLA-A∗02:01 allele. Regarding the high conservation of the
identified epitope and high frequency of HLA-A∗02:01 allele
in human population, it can be speculated that ∼20% of
the individuals exposed to divergent NoV genotypes, will
develop strong CD8+ T cell responses to this 10-mer epitope.
While NoV blocking antibodies are largely genotype specific,
a role of T cells targeted to broadly conserved epitopes, as
described in here, may be of large significance. However, the
role and importance of this epitope as well as overall T cell
responses in protection from NoV infection needs to be further
investigated.
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